Ophthalmology

Valeant to Sell $1.75B in Stock to Fund Bausch + Lomb Acquisition

Valeant Pharmaceuticals, based in Laval, Quebec, has announced plans to sell $1.75 billion in stock to support its acquisition of Bausch + Lomb, according to a PharmaLive report.

Carrie Pallardy

Tuesday, June 18th, 2013

Valeant will pay $4.5 billion to acquire Bausch + Lomb and another $4.2 billion to cover the ophthalmic product company’s debt.

Valeant did not disclose the number of shares it plans to sell.

More Articles on Ophthalmology:
EyeCRO, Calvert Labs Partner to Perform Preclinical Studies of Ophthalmic Drugs
ForSight VISION5 Names John Maroney President, CEO
16 Statistics on Ophthalmologist Burnout

Next Up in Ophthalmology

Illinois eye practice suffers data incident

Bloomington, Ill.-based VisionPoint Eye Center has notified certain patients that their information may have been affected in a data security…

By: Cameron Cortigiano
Tuesday, December 16th, 2025
Ophthalmologists oppose bill expanding laser procedure certifications

Ophthalmologists have raised concerns about a bill in the New Hampshire State House that would expand laser treatment certifications for…

By: Cameron Cortigiano
Wednesday, December 10th, 2025
Parker Cornea breaks ground on ophthalmology ASC

The Parker Cornea Eye Institute has broken ground on a 6,500-square-foot ASC in Birmingham, Ala. The ophthalmology-focused facility will include…

By: Cameron Cortigiano
Thursday, November 20th, 2025

Comments are closed.

From manual to manageable: How AI and partnerships are transforming urology RCM

Next Up in Ophthalmology

Illinois eye practice suffers data incident

Ophthalmologists oppose bill expanding laser procedure certifications

Parker Cornea breaks ground on ophthalmology ASC

Join the 40,000+ ASC leaders who start their day with Becker's